

AJANTA PHARMA LIMITED

CIN : L24230MH1979PLC022059

Registered & Corporate Office: 'Ajanta House', 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India

Contact Person: Mr. Gaurang Shah, Company Secretary | Tel.: +91 22 6606 1000 | Fax: +91 22 6606 1200

E-mail: investorgrievance@ajantapharma.com | Website: www.ajantapharma.com

FOR THE ATTENTION OF THE ELIGIBLE SHAREHOLDERS OF AJANTA PHARMA LIMITED ("COMPANY") IN RELATION TO THE OFFER TO BUYBACK OF NOT EXCEEDING 7,35,000 (SEVEN LAKH THIRTY FIVE THOUSAND) FULLY PAID-UP EQUITY SHARES OF FACE VALUE ₹ 2 EACH, REPRESENTING 0.84% OF THE TOTAL NUMBER OF EQUITY SHARES IN THE ISSUED, SUBSCRIBED AND PAID-UP EQUITY SHARE CAPITAL OF THE COMPANY, FROM ALL THE EXISTING SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF THE COMPANY AS ON THE RECORD DATE i.e. FRIDAY, NOVEMBER 13, 2020 ON A PROPORTIONATE BASIS, THROUGH THE "TENDER OFFER" PROCESS AT A PRICE OF ₹ 1,850/- (RUPEES ONE THOUSAND EIGHT HUNDRED AND FIFTY ONLY) PER EQUITY SHARE FOR AN AGGREGATE CONSIDERATION NOT EXCEEDING ₹ 135,97,50,000 (RUPEES ONE HUNDRED THIRTY FIVE CRORES NINETY SEVEN LAKHS AND FIFTY THOUSAND ONLY) EXCLUDING THE TRANSACTION COSTS.

Unless otherwise defined, capitalised terms used but not defined in this advertisement shall have the meaning assigned to such terms in the Letter of Offer

This advertisement ("**Advertisement**") is being issued by the Company pursuant to and in compliance with the circular issued by SEBI vide circular no. SEBI/CIR/CFD/DCR1/CIR/P/2020/83 dated May 14, 2020 read with SEBI circular no. SEBI/HO/CFD/DCR2/CIR/P/2020/139 dated July 27, 2020 (the "**Relaxation Circulars**") to supplement the Public Announcement dated November 4, 2020 that was published in all editions of the Business Standard, an English national daily and Business Standard, a Hindi national daily and the Mumbai edition of Navshakti, a regional language (Marathi) daily ("**Public Announcement**"), each with wide circulation on November 5, 2020, and the Letter of Offer dated November 25, 2020 ("**LoF**").

1. COMPLETION OF DISPATCH

In terms of the Relaxation Circulars and in light of the COVID-19 situation, the Letter of Offer along with Tender Form has been electronically dispatched to Eligible Shareholders holding Equity Shares as on the Record Date i.e. Friday, November 13, 2020 and whose email ids have been registered with Company/ as downloaded from depositories. The Company will not undertake any physical dispatch of the Letter of Offer and Tender Form in compliance with the Relaxation Circulars.

2. AVAILABILITY OF LETTER OF OFFER AND TENDER FORM

An Eligible Shareholder may access the Letter of Offer along with the Tender Form, on the website of the Company (www.ajantapharma.com), the Registrar to the Buyback (www.linkintime.co.in/Offer/Default.aspx), the Stock Exchanges i.e. NSE (www.nseindia.com), BSE (www.bseindia.com) and the Manager to the Buyback (www.indusind.com). Eligible Shareholder who have not registered their email ids with the depositories/ the Company, and who want to know their entitlement can do so by accessing the website of the Registrar at (www.linkintime.co.in/Offer/Default.aspx). Further, in case of non-receipt of Letter of Offer, the application can be made on a plain paper in writing signed by all Eligible Shareholders (in case of joint holding), stating name and address of the Eligible Shareholder(s), number of Equity Shares held as on the Record Date, Client ID number, DP Name, DP ID, beneficiary account number and number of Equity Shares tendered for the Buyback during the Tendering Period. For detailed procedure for tendering Equity Shares and settlement, please refer to section titled "*Procedure for Tender Offer and Settlement*" on Page 35 of Letter of Offer.

3. BRIEF SCHEDULE OF ACTIVITIES

Activity	Date
Date of Opening of the Buyback Offer	Thursday, December 03, 2020
Date of Closing of the Buyback Offer	Wednesday, December 16, 2020
Last date of receipt of the completed Tender Forms and other specified documents including physical Equity Share certificates by the Registrar	Friday, December 18, 2020
Last date of verification of Tender Forms by the Registrar	Tuesday, December 22, 2020
Last date of intimation regarding acceptance / non-acceptance of tendered Equity Shares by the Registrar	Wednesday, December 23, 2020
Last date of settlement of bids on the Stock Exchange	Thursday, December 24, 2020
Last date of dispatch of share certificate(s) by Registrar/ payment to shareholders/ return of unaccepted demat shares by Stock Exchange to Eligible Shareholders	Thursday, December 24, 2020
Last date of extinguishment of Equity Shares bought back	Wednesday, December 30, 2020

Note: Where last dates are mentioned for certain activities, such activities may take place on or before the respective dates.

4. CONTACT DETAILS

In case of any queries, including for receiving LoF and Tender Forms, please reach out to any of the below:

COMPANY	MANAGER TO BUYBACK OFFER	REGISTRAR TO THE BUYBACK OFFER
AJANTA PHARMA LIMITED 'Ajanta House', 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India Contact Person: Mr. Gaurang Shah, Company Secretary Tel: 022 6606 1000 Fax: 022 6606 1200 Email: investorgrievance@ajantapharma.com Website: www.ajantapharma.com	INDUSIND BANK LIMITED 11 th Floor, One India Bulls Centre, Tower 1, 841 Senapati Bapat Marg, Elphinstone Road, Mumbai - 400 013, Maharashtra, India Contact Person: Mr. Priyankar Shetty / Ms. Nikita Somani Tel: +91 (22) 7143 2206 Fax: +91 (22) 7143 2270 Email: apl.buyback@indusind.com Website: www.indusind.com	LINK INTIME INDIA PRIVATE LIMITED C-101, 1 st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India Contact Person: Mr. Sumeet Deshpande Tel: +91 22 4918 6200 Fax: +91 22 4918 6195 E-mail: ajantapharma.buyback2020@linkintime.co.in Website: www.linkintime.co.in

5. OTHER INFORMATION

- The information contained in this Advertisement is in accordance with the Relaxation Circulars.
- The Buyback Offer will be implemented through stock exchange mechanism made available by NSE. Details relating to the procedure for tendering the Equity Shares are more particularly set out in the LoF.
- The Advertisement will also be available on the websites of the Company (www.ajantapharma.com), the Registrar to the Buyback (www.linkintime.co.in), the Stock Exchanges i.e. NSE (www.nseindia.com), BSE (www.bseindia.com) and the Manager to the Buyback (www.indusind.com).

6. DIRECTORS' RESPONSIBILITY

As per Regulation 24(i)(a) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended, the Board of Directors of the Company accept full responsibility for the information contained in this Advertisement and confirms that this Advertisement contains true, factual and material information and does not contain any misleading information.

For and on behalf of the Board of Directors of **Ajanta Pharma Limited**

Sd/-
Yogesh Agrawal
Managing Director
(DIN: 00073673)

Sd/-
Rajesh Agrawal
Joint Managing Director
(DIN: 00302467)

Sd/-
Gaurang Shah
Company Secretary

Place: Mumbai

Date : November 26, 2020